Decheng Reports a Big APLN Buy

Steve Strazza
November 14, 2023

From the Desk of Steve Strazza and Alfonso Depablos

Today’s most significant insider transaction comes in a Form 4 filing by Decheng Capital Management, a hedge fund focused on investing in early-stage life science companies.

Decheng reported a purchase in the biotech company Alpine Immune Sciences $ALPN worth more than $4.6 million.

Article Sales Message

Know the trading behavior of …

  • Senators
  • House Of Representatives
  • C-Suite Executives
  • Hedge Fund Managers
  • Other Big-Power Players

Our experienced team of analysts work through the Form 4, 13D and 13G filings to provide you a list of the best trade ideas.

You need to have a subscription to access this content in full.

Log in or subscribe
Filed Under: